Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
107M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
78.2M
-
Shares change
-
+2.76M
-
Total reported value, excl. options
-
$1.34B
-
Value change
-
+$44.2M
-
Put/Call ratio
-
0.27
-
Number of buys
-
85
-
Number of sells
-
-52
-
Price
-
$17.13
Significant Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) as of Q1 2023
183 filings reported holding RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share as of Q1 2023.
ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.2M shares
of 107M outstanding shares and own 72.89% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (17.7M shares), BlackRock Inc. (5.47M shares), VANGUARD GROUP INC (4.53M shares), MAVERICK CAPITAL LTD (4.41M shares), WELLINGTON MANAGEMENT GROUP LLP (4.11M shares), STATE STREET CORP (4.02M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (3.24M shares), CITADEL ADVISORS LLC (2.66M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.87M shares), and GOLDMAN SACHS GROUP INC (1.65M shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.